Table 1.

Epilepsy syndromes and conditions (listed alphabetically) for which KDT has been consistently reported as more beneficial (>70%) than the average 50% KDT response (defined as >50% seizure reduction)

Angelman syndrome56, 57

Complex 1 mitochondrial disorders51, 55

Dravet syndrome35, 36

Epilepsy with myoclonic–atonic seizures (Doose syndrome)34, 37, 38

Glucose transporter protein 1 (Glut‐1) deficiency syndrome (Glut1DS)27, 29, 30, 31, 32

Febrile infection–related epilepsy syndrome (FIRES)44, 45, 46, 47

Formula‐fed (solely) children or infants48, 49

Infantile spasms10, 39, 40

Ohtahara syndrome50, 51, 52

Pyruvate dehydrogenase deficiency (PDHD)28

Super‐refractory status epilepticus44, 46, 53, 54

Tuberous sclerosis complex41, 42, 43